Welcome to another edition of “Research Worth Sharing” — a roundup of recent research that we’ve found interesting and which we hope might provide worthwhile insights to others as well.
Paternal exercise confers endurance capacity to offspring through sperm microRNAs
Why we are interested: We’ve spent a lot of time discussing the benefits of cardiorespiratory fitness for individual longevity. This animal study extends that idea by suggesting that endurance training in fathers can confer fitness advantages to male offspring—even when those offspring never exercise themselves.1 Central to this work is PGC-1α, a transcriptional coactivator widely regarded as the “master regulator” of mitochondrial biogenesis and oxidative metabolism, and a molecule long linked to endurance adaptations.
What they showed: The authors showed that male offspring of endurance-trained fathers had higher VO2max, lower lactate accumulation during exercise, and could achieve a higher maximal running speed before exhaustion compared to the offspring of sedentary fathers. The benefit seen in the offspring occurred without changes in traditional cardiac remodeling measures such as heart size or the amount of blood leaving the heart. Instead, adaptations were muscle-specific: offspring displayed a shift toward more oxidative fibers and away from glycolytic fibers in the calf muscle.
They then showed that many of these same benefits could be passed on by sedentary fathers who had exercise-like physiology because of a transgene that overexpressed PGC-1α in muscle. The sedentary offspring of such mice that did not inherit the transgene still benefitted from their fathers’ physiology, showing greater endurance, cardiorespiratory fitness, and other parameters similar to exercise-trained animals, suggesting that PGC-1α might play a key role in the father-to-pup benefits of exercise.
The authors traced this intergenerational signal to small RNAs carried in sperm. Transferring sperm small RNAs from trained fathers into wild-type embryos was sufficient to reproduce the endurance phenotype in offspring, indicating a causal role for these molecules. Endurance exercise and muscle-specific PGC-1α activation both remodeled sperm microRNA profiles, but these changes did not persist beyond one generation. Finally, several of the exercise-responsive sperm microRNAs identified in mice were also altered in sperm from endurance-trained humans compared with untrained individuals, strengthening the case that the epigenetic mechanisms described here extend beyond a single species.
Together, these findings offer yet another reason to prioritize endurance training—not only for personal health and longevity, but for its potential to influence the metabolic fitness of the next generation.
doi: 10.1016/j.cmet.2025.09.003
SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade
Why we are interested: Cancer is notoriously difficult to treat. Recent immune checkpoint inhibitor (ICI) drugs can produce dramatic, durable responses—but only in a subset of patients. It would be clinically valuable if an already-approved, widely available intervention could improve ICI efficacy, or even expand the pool of ICI responders.
What they showed: In this retrospective analysis, patients with advanced non-small cell lung cancer (NSCLC, stage III/IV) or melanoma (stage IV) survived longer when receiving a COVID-19 mRNA vaccine within 100 days of starting ICI therapy.2 For 36 month overall survival, patients with NSCLC receiving a COVID mRNA vaccine had a 49% reduced risk of dying (HR = 0.51, 95% CI = 0.37–0.71), with 30.8% surviving without vaccination for 36 months compared to 55.7% with the COVID vaccine. Similar results were seen for melanoma, with a 63% reduction in risk (HR = 0.37, 95% CI = 0.18–0.74) and 44.1% vs 67.6% surviving. The survival benefit was also reflected in median overall survival (20.6 months vs. 37.3 months for NSCLC; 26.7 months vs. not reached for melanoma at 40 months). Notably, similar associations were not observed with non-mRNA vaccines for influenza or pneumonia, suggesting this may not be a generic “vaccinated patients do better” effect.
ICI therapies work best in “immunologically hot” tumors, meaning the patient already has an ongoing (though insufficient) immune response to the cancer. PD-L1 expression is a common measurement of this immunological heat—the more tumor cells that express PD-L1, the greater the tumor’s resistance to an ongoing immune attack. Incredibly, even NSCLC patients with <1% cell expression of PD-L1 at first biopsy—considered poor candidates for ICI due to an “immunologically cold” baseline—showed a 47% reduction in mortality risk when vaccinated within 100 days (HR = 0.53, 95% CI = 0.36–0.78). mRNA vaccination may therefore be both enhancing ICI’s efficacy in the normal subset of NSCLC and melanoma patients and expanding ICI’s efficacy to include immunologically cold tumors.
That said, this study was observational—patients were not selected and randomly assigned to receive a vaccine or not—so confounding is an obvious concern. In particular, COVID-19 vaccine uptake has a documented “healthy vaccine” effect observed in the USA, in which vaccination was more frequent in healthier populations (and in some racial/ethnic groups) during the pandemic. There has also been a history of failures when combining immune adjuvants with ICIs in appropriately controlled RCTs—none have passed a Phase III trial—even when preclinical and observational data are strong.
A Phase III trial is reportedly being planned, so we will stay tuned as this research develops, but we’ll need to see data from that proper RCT before there’s adoption at cancer treatment centers.
Still, this study adds to a growing body of evidence that some vaccines can have broadly positive immunological effects beyond their originally intended targets—as we’ve discussed for the shingles vaccine and cognitive decline before.
doi:10.1038/s41586-025-09655-y
Our research team spends hundreds of hours each month vetting studies and distilling dense literature to deliver evidence-informed insights on health and longevity. If you find value in our work, consider becoming a premium member and supporting our mission.
Treating Alzheimer’s Disease Using Light and Sound
Why we are interested: Pharmaceutical treatments for Alzheimer’s Disease (AD) are largely underwhelming, carrying significant risks of severe side effects while being only modestly effective at slowing disease progression. There is enormous upside potential for an AD treatment that avoids the considerable burdens of current-generation therapeutics, especially one performed in the comfort of patients’ own homes.
What they showed: The OVERTURE clinical trial investigates a different class of AD therapy: sensory stimulation, provided by a wearable headset and performed at home.3 Cognito’s CogTx-001 headset delivers flashing light and sound at 40Hz, intended to entrain a high-frequency brainwave pattern in the user—a type of pattern shown to strengthen neural connectivity and activate the brain’s waste-clearance systems in preclinical models. Researchers performed a randomized, double-blind, sham-controlled trial (2:1 active:sham, N=53), run for six months in adults 50+ with mild-to-moderate Alzheimer’s. Participants used the device one hour per day at home, resting with the eyes closed; the sham condition used non-40 Hz, randomly fluctuating stimulation.
The intervention showed an exceptionally strong safety profile: side effects were mild (e.g., headache and tinnitus in the active group), no serious treatment-related safety concerns were observed, and participants used the device consistently throughout the study (>80% daily adherence in both groups). Alongside this, there were encouraging signals of clinical benefit—most notably in everyday functioning, where people receiving the active treatment had an 84% slower functional decline in activities of daily living over six months compared with those receiving a sham treatment. Results for thinking and memory were mixed: one widely used screening test (the Mini-Mental State Examination, or MMSE) showed a 74% slower progression of symptoms, while two other cognitive tests showed no meaningful difference between groups.
Good safety and high adherence are as critical as they are difficult to obtain in AD trials. Still, the measures of efficacy leave something to be desired—no change was observed in amyloid β aggregates in the brain and the cognitive tests were contradictory, yet strong positive correlations existed for activities of daily living and increased brain volume. In other words, there’s enough positive here to warrant some hope, but not enough to act on until a Phase III trial is completed and published.
doi: 10.3389/fneur.2024.1343588
Sympathetic-parasympathetic system deregulation theory of aging
Why we are interested: Aging is the primary risk factor for most chronic diseases, yet the biological mechanisms that drive aging remain poorly understood. Numerous theories of aging have been proposed, each emphasizing different aspects of biology, but none have provided a complete explanation. As a result, new theories that offer deeper insight into the aging process, including addressing mechanisms not originally proposed in the hallmarks of aging, are of considerable interest. Such frameworks could help clarify which cellular processes drive physical and cognitive decline, informing the development of interventions aimed at delaying or preventing multiple diseases simultaneously, rather than treating them individually.
What they discussed: This position piece proposes that dysregulation of the sympathetic and parasympathetic nervous systems (SNS and PNS, respectively) is a unifying framework for the aging process.4 The SNS and PNS are the two main branches of the autonomic nervous system, which regulates involuntary physiological functions such as heart rate, breathing, and metabolism. The SNS mediates the “fight or flight” response, while the PNS, primarily via the vagus nerve, supports “rest and digest” functions that promote recovery and homeostasis. The authors argue that chronic SNS activation can drive several hallmarks of aging, while activation of the PNS may balance this out. Take chronic inflammation (“inflammaging”), for example: activation of the SNS in response to injury or illness stimulates the production of pro-inflammatory molecules to repair the damage while under normal circumstances, a balanced PNS facilitates the resolution of the inflammatory response, preventing a persistent inflammatory state.
The authors extend the rationale that sympathetic-parasympathetic dysregulation underlies aging to several other hallmarks of aging, including mitochondrial dysfunction and epigenetic alterations. For each, an intact PNS activity will in theory counterbalance these stress-related processes and restore physiological equilibrium. As such, according to this model, over time the nervous system drifts towards stronger sympathetic function, causing sustained activation of stress pathways that contributes to physical and cognitive decline.
If correct, this specific proposed theory offers a potential therapeutics aimed at activating the PNS (e.g., vagus nerve stimulation), making it a particularly appealing prospect.
doi:10.1038/s41514-025-00293-2
For a list of all previous weekly emails, click here.
References
1. Yin X, Anwar A, Yan L, et al. Paternal exercise confers endurance capacity to offspring through sperm microRNAs. Cell Metab. 2025;37(11):2167-2184.e8. doi:10.1016/j.cmet.2025.09.003
2. Grippin AJ, Marconi C, Copling S, et al. SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade. Nature. 2025;647(8089):488-497. doi:10.1038/s41586-025-09655-y
3. Hajós M, Boasso A, Hempel E, et al. Safety, tolerability, and efficacy estimate of evoked gamma oscillation in mild to moderate Alzheimer’s disease. Front Neurol. 2024;15:1343588. doi:10.3389/fneur.2024.1343588
4. Errico JP, Ben-Azu B, Gargus M, Newell Rogers MK, Tremblay MÈ. Sympathetic-parasympathetic system deregulation theory of aging. NPJ Aging. 2025;11(1):100. doi:10.1038/s41514-025-00293-2
